A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A

Inclusion Criteria:

- Male patients with severe congenital haemophilia A (FVIII activity level below 1%)

- Weight above or equal to 10 kg - Documented history of 150 exposure days (ED) to FVIII
products for patients aged 6-11 years and above 50 ED to FVIII products for patients
aged 0-5 years

Exclusion Criteria:

- Any history of FVIII inhibitors